Screener
Lifecore Biomedical, Inc. LFCR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Lifecore Biomedical, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q3 2026
- Accession
- 0001005286-26-000033
| (in thousands, except share and per share amounts) | Three months ended / June 30,2026 | Three months ended / May 25,2025 | Six months ended / June 30,2026 | Six months ended / May 25,2025 |
|---|---|---|---|---|
| Loss before income taxes | (6,133) | (1,114) | (21,070) | (15,891) |
| Income tax expense | (23) | (33) | (66) | (25) |
| Net loss | (6,156) | (1,147) | (21,136) | (15,916) |
| Preferred stock dividends | (924) | (852) | (1,831) | (1,689) |
| Accretion of preferred stock to redemption value | (47) | (48) | (94) | (96) |
| Loss available to common stockholders | $(7,127) | $(2,047) | $(23,061) | $(17,701) |
| Loss per share, basic and diluted | $(0.19) | $(0.06) | $(0.61) | $(0.48) |
| Weighted average shares outstanding, basic and diluted | 37,574,538 | 37,007,838 | 37,526,230 | 37,014,204 |
Item 1. Financial
FAQ
- What is Lifecore Biomedical, Inc.'s EPS (diluted)?
- Lifecore Biomedical, Inc. (LFCR) reported EPS (diluted) of -$0.19 in Q2 2026.
- What is the long-term trend for Lifecore Biomedical, Inc.'s EPS (diluted)?
- Over 2 years (2022 to 2025), Lifecore Biomedical, Inc.'s EPS (diluted) has grown at a -43.7% compound annual growth rate (CAGR), from -$3.97 to -$1.26.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Lifecore Biomedical, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude